OverviewSuggest Edit

Acceleron Pharma is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of treatments for hematologic, neuromuscular, and pulmonary diseases. The company specializes in TGF-beta biology and protein engineering to regulate cellular growth and repair.

TypePublic
Founded2003
HQCambridge, US
Websiteacceleronpharma.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2019)237(+37%)
Job Openings19
Revenue (FY, 2019)$74 M(+429%)
Share Price (May 2020)$98.6

Key People/Management at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

CFO
Jay T. Backstrom

Jay T. Backstrom

EVP, Head of Research and Development
Todd James

Todd James

SVP, Corporate Affairs and Investor Relations
James Desiderio

James Desiderio

SVP, Regulatory and Quality
Sujay Kango

Sujay Kango

EVP, Chief Commercial Officer
Show more

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney St
Show all (1)

Acceleron Pharma Financials and Metrics

Acceleron Pharma Revenue

Acceleron Pharma's revenue was reported to be $73.99 m in FY, 2019 which is a 428.9% increase from the previous period.
USD

Revenue (Q1, 2020)

4.3m

Net income (Q1, 2020)

(50.9m)

EBIT (Q1, 2020)

(51.6m)

Market capitalization (22-May-2020)

5.3b

Closing stock price (22-May-2020)

98.6

Cash (31-Mar-2020)

277.5m

EV

5.1b
Acceleron Pharma's current market capitalization is $5.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

13.5m14.0m74.0m

Revenue growth, %

(51%)4%429%

General and administrative expense

33.7m34.5m56.5m

R&D expense

89.7m103.9m154.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

3.7m3.1m3.0m3.2m3.7m3.3m2.8m27.7m4.2m4.3m

General and administrative expense

7.8m11.4m7.5m7.4m7.7m8.7m10.8m14.0m15.5m18.3m

R&D expense

21.7m21.6m21.1m23.4m25.9m24.7m32.8m34.8m37.6m37.7m

Operating expense total

29.6m33.0m28.6m30.9m33.6m33.3m43.6m48.8m53.1m55.9m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

100.2m144.1m237.7m

Accounts Receivable

3.6m7.0m8.5m

Prepaid Expenses

4.4m7.7m10.0m

Current Assets

285.2m306.0m449.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

33.2m30.7m239.0m69.7m79.6m112.4m214.5m163.6m169.5m277.5m

Accounts Receivable

3.6m2.9m2.9m3.2m3.7m3.3m2.8m5.4m6.9m

Prepaid Expenses

4.1m3.1m3.3m5.2m7.5m7.1m7.9m9.5m10.6m9.3m

Current Assets

149.0m148.4m343.4m300.3m299.1m318.3m448.3m445.7m443.5m432.2m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(108.5m)(118.9m)(124.9m)

Depreciation and Amortization

2.8m3.7m3.9m

Accounts Payable

(504.0k)(673.0k)1.9m

Cash From Operating Activities

(76.7m)(94.7m)(93.8m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(25.4m)(55.1m)(80.5m)(26.2m)(55.2m)(84.1m)(38.1m)(55.9m)(101.3m)(50.9m)

Depreciation and Amortization

541.0k1.2m2.0m904.0k1.9m2.9m2.2m1.9m2.9m996.0k

Accounts Payable

(778.0k)71.0k(566.0k)591.0k183.0k80.0k3.5m3.1m1.4m1.6m

Cash From Operating Activities

(21.9m)(39.1m)(55.9m)(23.4m)(45.6m)(65.7m)(26.3m)(40.5m)(77.6m)(46.5m)
USDY, 2020

EV/EBIT

-98 x

EV/CFO

-108.6 x

Financial Leverage

1.1 x
Show all financial metrics

Acceleron Pharma Operating Metrics

FY, 2017FY, 2018FY, 2019

Patent Applications

492 505 637

Patents Issued

635 708 788
Show all operating metrics

Acceleron Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Acceleron Holding Ltd.
Acceleron Securities Corp.

Acceleron Pharma Revenue Breakdown

Embed Graph

Acceleron Pharma revenue breakdown by business segment: 18.9% from Cost-Sharing and 81.1% from License and Milestone

Acceleron Pharma Online and Social Media Presence

Embed Graph

Acceleron Pharma Company Culture

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Acceleron Pharma News and Updates

Acceleron Pharma stock soars more than 50% on hypertension drug study

Acceleron Pharma Inc. shares surged in the extended session late Monday after the biotech drug maker said its hypertension drug hit key goals in a mid-stage clinical trial. Acceleron shares soared 56% after hours, following a 1.6% rise to close Monday at $52.87. At Monday's close, the company had a…

Acceleron Pharma stock down 4% after company halts treatment trial

Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type of muscular dystrophy showed no evidence of benefits relative to a placebo. The company has stopped further clinical trials, saying it was "di…

Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia

U.S. Food and Drug Administration sets target action date of April 4, 2020 for myelodysplastic syndromes indication.read more

Key Findings of the Growth/Differentiation Factor 8 Market | Acceleron Pharma, Inc., Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company

HTF MI published a new industry research that focuses on Growth/Differentiation Factor 8 market and delivers in-depth market analysis and future prospects of Global Growth/Differentiation Factor 8 market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Acceleron Pharma Blogs

Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes

Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes Brian.Hoenig@n… Thu, 04/30/2020 - 16:17 Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Th…

Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension

Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension Content Import Wed, 04/08/2020 - 07:05 Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension Apr 08, 2020 …

Acceleron Announces Retirement of Director Jean George

Acceleron Announces Retirement of Director Jean George Content Import Tue, 04/07/2020 - 16:06 Acceleron Announces Retirement of Director Jean George Apr 07, 2020 This release is a backfill from a News Wire General CAMBRIDGE, Mass.…

U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Brian.Hoenig@n… Fri, 04/03/2020 - 17:08 U.S. Food and Drug Administration (FDA) Approves …

New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia

Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- Bristol-Myers Squibb Company (NYSE:BMY) and Acceler…

Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease

Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease Content Import Mon, 03/09/2020 - 16:05 Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease Mar 09…
Show more

Acceleron Pharma Frequently Asked Questions

  • When was Acceleron Pharma founded?

    Acceleron Pharma was founded in 2003.

  • Who are Acceleron Pharma key executives?

    Acceleron Pharma's key executives are Habib Dable, Kevin McLaughlin and Jay T. Backstrom.

  • How many employees does Acceleron Pharma have?

    Acceleron Pharma has 237 employees.

  • What is Acceleron Pharma revenue?

    Latest Acceleron Pharma annual revenue is $74 m.

  • What is Acceleron Pharma revenue per employee?

    Latest Acceleron Pharma revenue per employee is $312.2 k.

  • Who are Acceleron Pharma competitors?

    Competitors of Acceleron Pharma include Supernus Pharmaceuticals, Theravance Biopharma and GBT (Global Blood Therapeutics).

  • Where is Acceleron Pharma headquarters?

    Acceleron Pharma headquarters is located at 128 Sidney St, Cambridge.

  • Where are Acceleron Pharma offices?

    Acceleron Pharma has an office in Cambridge.

  • How many offices does Acceleron Pharma have?

    Acceleron Pharma has 1 office.